Martin Dreyling, MD, Ludwig Maximilian University of Munich, discusses results of the TRIANGLE study testing the addition of ibrutinib to treat mantle cell lymphoma.
Mantle cell lymphoma is a rare form of malignant non-Hodgkin lymphoma affecting B lymphocytes in the lymph nodes in a region called the “mantle zone”. Common symptoms include tumors near the lymph nodes, fever, involuntary weight loss, and night sweats.
The TRIANGLE clinical trial was a randomized, open-label, three-arm study evaluating the addition of ibrutinib to standard treatment with autologous stem cell transplantation (ASCT). Ibrutinib is an oral, covalent BTK inhibitor that disrupts B cell processes. The results of the study were presented at ASH 2024.
The primary outcome of the TRIANGLE study was failure-free survival (FFS). Secondary outcomes included overall survival (OS). 870 patients were randomized into three arms: Arm A, those on standard treatment; Arm A+I, those on standard treatment with addition of ibrutinib with ASCT; and Arm I, those on ibrutinib treatment without ASCT.
At a median follow-up time of 53 months, Arm A+I and Arm A did not show better FFS over Arm I. However, a 5% significance level was seen with FFS-superiority of Arm I over Arm A and FFS-superiority of Arm A+I over Arm A was at 86% (A+I) and 75% (A) FFS. Additionally, when compared to Arm A, OS was prolonged in arms A+I (three year OS of 90%) and I (91%).
For more information, click here.
To learn more about mantle cell lymphoma and other rare cancers, visit https://checkrare.com/diseases/cancers/